Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference51 articles.
1. New chemotherapeutic agents prolong survival and improve qualitiy of life in non-small cell lung cancer;Bunn;Clin. Cancer Res.,1998
2. New aspects in the staging of lung cancer;Bülzebruck;Cancer,1992
3. Combination chemotherapy versus single agent followed by combination chemotherapy in stage IV non-small cell lung cancer;Bonomi;J. Clin. Oncol.,1998
4. A randomized trial of three cisplatin-containing regimens in advanced non-small cell lung cancer (NSCLC);Crino;Cancer Chemother. Pharmacol.,1990
5. Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer;Elliot;Eur. J. Cancer Clin. Oncol.,1984
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer;Lung Cancer;2010-03
2. Tumoral Expression of TXR1 and TSP1 Predicts Overall Survival of Patients with Lung Adenocarcinoma Treated with First-line Docetaxel-Gemcitabine Regimen;Clinical Cancer Research;2009-05-12
3. Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report;Journal of Clinical Oncology;2009-03-20
4. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first‐line chemotherapy with second‐line crossover in patients with advanced nonsmall cell lung cancer;Cancer;2008-07-15
5. A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC);Lung Cancer;2007-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3